# Diabetes Research Hub — Monitor Report
**Run date:** 2026-06-29 (automated, scheduled)
**Scope:** Review-only. No existing files modified.
**Prior monitor report:** monitor_report_2026-06-28.md

---

## TL;DR — what's actionable

1. **Orforglipron (Foundayo) is now FDA-approved** (Apr 1, 2026, obesity indication; T2D filing expected late 2026). The hub tracks orforglipron as a key therapy and it is the single biggest mover in both the trial set and the literature this week. **Update the tracker to reflect approved status.** [Likely → Certain on approval; Likely on T2D timeline]
2. **18 new trials appeared in the last 7 days**, including a 5-trial AstraZeneca Phase 3 cluster (oral GLP-1 *elecoglipron*), a Lilly orforglipron head-to-head Phase 3 vs dulaglutide, a Roche *enicepatide* Phase 3, and a University of Florida T1D immunologic Phase 3 (PRISE). [Certain — from snapshot diff]
3. **Today's daily diff is quiet:** 0 new/removed/changed trials Jun 28→29; PubMed churned 68 in / 69 out with 7 cross-domain papers. [Certain]
4. **Gap analysis is 6 days old** (report) / data file 2026-06-23. Two of the top-5 gaps map directly onto Tier 1 doctrine areas (Drug Repurposing, Health Equity) — worth a verification pass. [Certain on dates]

---

## File System Status

All four core feeds refreshed this morning (2026-06-29 ~07:05):

| File | Last modified | Status |
|------|---------------|--------|
| clinical_trials_latest.json | 2026-06-29 07:05 | Fresh (838 trials) |
| pubmed_recent_latest.json | 2026-06-29 07:05 | Fresh (162 papers) |
| hub_monitor_report.md | 2026-06-29 07:10 | Fresh |
| literature_gap_report.md | 2026-06-28 14:07 | 1 day old |
| literature_gap_data.json | 2026-06-23 16:09 | **6 days old** |

- New files since last scan (5): clinical_trials_snapshot_2026-06-29, pubmed_recent_snapshot_2026-06-29, monitor_report_2026-06-28, iterate_run_report_2026-06-28, Analysis/Scripts/run_daily_local.py.
- hub_monitor flags **757 result files older than 14 days** — these are overwhelmingly historical daily snapshots (CT snapshots run back to 2026-03-15), so this is expected accumulation, not staleness of live feeds. No action needed beyond optional archival.
- No removed/missing expected files.

---

## Clinical Trial Changes

**Daily diff (2026-06-28 → 2026-06-29):** 0 new, 0 removed, 0 status changes, 0 new results. [Certain]

**7-day diff (2026-06-22 → 2026-06-29): 18 new trials.** The signal is a wave of late-stage oral incretin programs plus one T1D immunotherapy:

| NCT | Phase / Status | Sponsor | Note |
|-----|----------------|---------|------|
| NCT07662044 / 109 / 135 / 213 / 664553 | Phase 3 / Not yet recruiting | **AstraZeneca** | 5-trial Phase 3 program — oral GLP-1 **elecoglipron**. New competitive entrant. |
| NCT07668336 | Phase 3 / Not yet recruiting | **Eli Lilly** | **Orforglipron** vs dulaglutide head-to-head |
| NCT07668388 | Phase 2 / Not yet recruiting | **Novo Nordisk** | Undisclosed metabolic agent, dose-ranging |
| NCT07670416 | Phase 3 / **Recruiting** | Hoffmann-La Roche | **Enicepatide** (RO7795068) |
| NCT07659574 | Phase 3 / Not yet recruiting | United Bio-Technology | UBT251 (T2D) |
| NCT07670650 | Phase 3 / Not yet recruiting | University of Florida | **PRISE** — T1D personalized immunologic surveillance |
| NCT07507708 | NA / Recruiting | UVA (Sue Brown) | Self-adjusting closed-loop |
| + ~5 behavioral/device/completed | — | various | Lower priority |

**Key Phase 3 RECRUITING trials still active (47 total).** Highest-relevance to hub focus:

- **Vertex VX-880 / zimislecel** — NCT04786262 and NCT06832410 (Phase 3, recruiting). Cell-therapy cure program; Tier 1 cross-reference.
- **Lilly baricitinib in T1D** — NCT07222137 (delay Stage 3) and NCT07222332 (preserve beta-cell function, pediatric). Repurposed JAK inhibitor.
- **Novo CagriSema** — NCT07564414 (Phase 3, recruiting).
- **Novo insulin icodec in T1D** — NCT07076199.
- **Sanofi teplizumab** — NCT07088068 (vs placebo).
- **vTv cadisegliatin (glucokinase activator)** — NCT06334133. Relevant to the Glucokinase gap cluster below.

**Results posted in last 7 days (4):** NCT00248352, NCT04334109, NCT07465926, NCT07566299 — all behavioral / care-delivery / early GLP-1+SGLT2 add-on studies (status NA, no registered phase). Low priority; none are flagship Phase 3 readouts.

---

## PubMed Highlights

162 unique papers across 16 alert domains (30-day lookback). Daily snapshot diff (Jun 26→29): **68 new, 69 dropped.**

**Cross-domain papers (13 total — highest value).** Notable:

- **[42358678]** *Early proteomic and metabolomic signatures in diabetes associated with progression to diabetic retinopathy* — spans **Biomarker + Complications + Multi-Omics** (triple-domain). Directly on Tier 1 area #1 (Multi-Omics Biomarker Integration). [Certain it's cross-domain; Bronze on relevance]
- **[42296503]** *Benefits and Harms of Pharmacologic Treatments in Adults With Overweight/Obesity* — spans orforglipron + retatrutide (two tracked therapies in one synthesis).
- **[42332392] / [42295172] / [42327726]** — teplizumab cluster (T1D Immunotherapy × Key Therapy), tracking the expanded Tzield indication.
- **[42363271]** *Efficacy and safety of orforglipron in obesity with T2D — GRADE meta-analysis* (GLP-1 New × Key Therapy).
- **[42364790]** microbiome-targeted therapy for diabetic foot ulcers (Microbiome × Gene Therapy).

**Key-therapy mentions this cycle:** all 8 tracked therapies hit. Heaviest literature volume around **CagriSema** (4 papers — NCT cluster 42251856/859/860 plus 42180166, consistent with ADA 2026 readouts), **orforglipron** (4), **icodec** (5), **dapagliflozin** (5), **retatrutide** (4), **teplizumab** (5), **baricitinib** (5). **zimislecel** registered 2 hits.

**Volume trend:** stable, no anomalous domain spikes. Roughly even ~2-paper representation per domain in the latest snapshot's domain index.

---

## Gap Analysis Summary

Source: literature_gap_report.md (2026-06-28), 30 domains, 435 pairs. **Validation level: BRONZE** (single analytical source; expert confirmation pending per Research Doctrine).

**Top 5 under-researched intersections (Gap Score 100):**

1. Beta Cell Regen × Health Equity (0 joint pubs)
2. Insulin Resistance × Islet Transplant (1)
3. Islet Transplant × Drug Repurposing (0)
4. Islet Transplant × Health Equity (0)
5. Gene Therapy × LADA (0)

**Tier 1 alignment (from RESEARCH_DOCTRINE.md):**

- **Drug Repurposing** is Tier 1 area #4. Gaps #3 (Islet Transplant × Drug Repurposing) and #8/#12/#13 (Glucokinase, Health Equity, LADA × Drug Repurposing) are direct contribution candidates — and gap #3 now has a live mechanistic hook via the baricitinib-in-islet-tolerance paper [42013280] surfaced this cycle.
- **Health Equity / Epidemiological analysis** is Tier 1 area #6. Five of the top gaps involve Health Equity, all with 0–1 joint pubs.
- **Multi-Omics** is Tier 1 area #1, reinforced by cross-domain paper [42358678].

Caveat (per doctrine): these are *relative* bibliometric gaps and may reflect terminology mismatch rather than true whitespace. Verify with combined-term PubMed searches before acting.

---

## Breaking News (web check, last ~7–90 days)

Only genuinely significant items flagged:

- **Orforglipron (Foundayo) — FDA approved.** First oral small-molecule GLP-1; approved **Apr 1, 2026** for obesity/overweight. **T2D indication not yet granted; Lilly filing expected late 2026.** Lancet head-to-head showed superiority vs oral semaglutide on glucose and weight. Directly relevant — hub tracks orforglipron and holds multiple orforglipron Phase 3 trials. [Certain on approval; Likely on T2D timeline]
- **Pediatric Tzield (teplizumab)** — FDA approval for pediatric Stage 3 T1D reported **June 10, 2026** (expansion beyond the April 2026 Stage 2 ages-1+ expansion). Matches the teplizumab literature cluster this cycle. [Likely]
- **Survodutide (Boehringer) SYNCHRONIZE-1** — Phase 3 obesity, up to 16.6% weight loss at 76 wks; full data at **ADA 2026 Scientific Sessions (June)**. Not currently in the hub's tracked-therapy list — consider adding. [Likely]

(Other 2026 approvals already in the record: Awiqli/insulin icodec Mar 26; Langlara insulin glargine biosimilar Apr 29; first generic dapagliflozin.)

---

## Recommended Actions

1. **Update Diabetes_Research_Tracker.xlsx**: mark orforglipron as FDA-approved (obesity, Apr 1 2026), flag T2D filing pending late 2026. Add the new Lilly orforglipron Phase 3 (NCT07668336). [Priority: high]
2. **Add the AstraZeneca elecoglipron Phase 3 cluster** (NCT07662044/109/135/213, NCT07664553) and Roche enicepatide (NCT07670416) to the competitive-landscape view — new late-stage oral incretin entrants. [high]
3. **Flag University of Florida PRISE trial (NCT07670650)** for the T1D immunotherapy watch list. [medium]
4. **Re-run gap analysis** — `python project1_literature_gap_analysis.py`. Underlying data file is 6 days old; refresh so the Tier-1-aligned Drug Repurposing / Health Equity gaps reflect this week's literature. [medium]
5. **Verify gap #3 (Islet Transplant × Drug Repurposing)** with a combined-term PubMed search — paper [42013280] (baricitinib → islet tolerance) suggests a real mechanistic bridge; candidate for a Tier 1 repurposing write-up. [medium]
6. **Review cross-domain paper [42358678]** (proteomic/metabolomic retinopathy signatures) — aligns with Tier 1 Multi-Omics Biomarker Integration. [medium]
7. **Consider adding survodutide** to the tracked-therapy list given the SYNCHRONIZE-1 readout. [low]
8. Optional housekeeping: archive CT/PubMed daily snapshots older than ~30 days to quiet the 757-stale-file flag. [low]

---

## Evidence / Validation Notes (per Research Doctrine)

- Trial counts, snapshot diffs, PubMed cross-domain and therapy tags: **Certain** — read directly from this morning's JSON feeds.
- Gap classifications: **Bronze** — single analytical source, expert validation pending.
- FDA/clinical-news items: **Likely** — corroborated by multiple web sources (PR Newswire, FDA, AJMC, Drugs.com); approval dates cross-checked.
- This run made **no modifications** to existing hub files.

---
*Generated by diabetes-hub-monitor (scheduled task) — 2026-06-29*
